Context: To date only 18 patients with aggressive pituitary tumors or carcinomas treated with
temozolomide have been reported. Increased expression of O 6-methylguanine-DNA …

Objectives Only few retrospective studies have reported an efficacy rate of temozolomide
(TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated …

Pituitary carcinomas are rare, accounting for about 0· 2% of all pituitary tumours. They
represent a challenge to clinical practice in both diagnosis and treatment. They may present …

Temozolomide, an orally administered alkylating agent, is used to treat malignant gliomas.
Recent reports also have documented its efficacy in the treatment of pituitary adenomas and …

Eur J Clin Invest 2011; 41 (10): 1133–1148 Abstract Background Aggressive pituitary
tumours are associated with substantial morbidity and mortality. Treatment options are often …

Temozolomide is effective in some patients with progressive pituitary adenoma or
carcinoma. We report a survey study of Italian patients treated with Temozolomide because …

We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years,
presenting aggressive pituitary tumors. In all the patients tested O6‐methylguanine‐DNA …

Objective The prognosis of either pituitary carcinoma or aggressive pituitary adenoma
resistant to standard therapies is poor. We assessed the efficacy of treatment with …

Temozolomide (TMZ) has been shown as an effective treatment option in aggressive
pituitary adenomas and carcinomas. This review analyses the published case series and …

Context: The typically indolent behavior of pituitary tumors is juxtaposed with high rates of
tumor cell invasion into adjacent dural structures, and occasional aggressive behavior …